Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
BetaGlue Technologies has appointed four new managers, strengthening the team across strategic fields for its business development: Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni joined the company in September in the Clinical Research, Manufacturing and Quality areas.
Betty Polikar was Head of the Startup Unit of the Center of Excellence at “Bambino Gesù” Children’s Hospital in Rome and will now bring her experience as Head of Clinical Operations of BetaGlue. Gianluca De Danieli is taking on the role of Head of Clinical Development, Pietro Bubba Bello will be Head of Manufacturing & Operations, and Gaia Bisaccioni is joining the company as Head of Quality. The three managers join the company from Novartis, after having worked at Advanced Accelerator Applications (AAA).
At the same time, clinical progresses are ongoing for BAT-90, the advanced cancer radiotherapy platform developed by BetaGlue: recently, the first three breast cancer patients have been treated at New Hospitals in Tblisi, Georgia. This is the second “first in man” clinical trial, after the one in liver cancer patients.
Riccardo Palmisano, Executive Chairman, and Antonino Amato, CEO/CMO of BetaGlue Technologies, declared: “The appointment of four new highly skilled leaders with proven experience in Life Sciences’ key areas, along with the increased financial assets stemming from the successful closing of our recent financing round, enables BetaGlue to continue with confidence toward achieving the ambitious goal of creating value for both Patients and Shareholders”.
